Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Receptor-interacting serine/threonine kinase 2 (RIPK2) is a vital immunomodulator that plays critical roles in nucleotide-binding oligomerization domain 1 (NOD1), NOD2, and Toll-like receptors (TLRs) signaling. Stimulated NOD1 and NOD2 interact with RIPK2 and lead to the activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPK), followed by the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12/23. Defects in NOD/RIPK2 signaling are associated with numerous inflammatory diseases, including asthma, sarcoidosis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), multiple sclerosis, and Blau syndrome. As RIPK2 is a crucial element of innate immunity, small molecules regulating RIPK2 functions are attractive to establish novel immunotherapies. The increased interest in developing RIPK2 inhibitors has led to the clinical investigations of novel drug candidates. In this review, we attempt to summarize recent advances in the development of RIPK2 inhibitors and degraders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“formate significantly increased genes associated with Tc1 activation and differentiation, such as receptor-interacting serine/threonine-protein kinase 2 (Ripk2)64, zinc transporter ZIP8 (Slc39a8)65, furin66, poly (ADP-ribose) polymerase 1 (Parp1)67,68, ezrin (Ezr)69, and interferon regulatory factor 8 (Irf8)70–72.”
From Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy (2025) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591 · cited 1×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · cited 1×
“In analogous to the EGFR T90Mmutation that renders resistance to gefitinib (Kobayashi et al., 2005), the T95M point mutation of RIPK2 in the ATP binding pocket abolished the inhibitory activities of both erlotinib and gefitinib, indicating that these compounds directly inhibited RIPK2.”
BackgroundPROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · cited 1×
“This catalytic nature of PROTACs distinguishes them from traditional inhibitors (Békés et al., 2022; Hu and Crews, 2022).”
BackgroundNod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection
Girardin, S. E., Boneca, I. G., Viala, J., Chamaillard, M., Labigne, A., Thomas, G., Philpott, D. J., & Sansonetti, P. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200651200 · Cited by 2,408
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 1,971 · cited 1×
“Modern immunotherapies focus on precisely regulating immune responses (Kany et al., 2019; McInnes and Gravallese, 2021).”
BackgroundDe-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling
Wertz, I. E., O'Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R., Boone, D. L., et al. (2004) · Nature · doi:10.1038/nature02794 · Cited by 1,856 · cited 1×
“The deubiquitinating enzyme A20 downregulates NODs/RIPK2 signaling by removing Lys63-pUb chains from RIPK2 (Wertz et al., 2004).”
BackgroundActivation and signaling of the p38 MAP kinase pathway
ZARUBIN, T., & HAN, J. (2005) · Cell Research · doi:10.1038/sj.cr.7290257 · Cited by 1,707 · cited 1×
“The MAPK signaling pathways regulate several cellular processes, including proliferation, differentiation, inflammation, and apoptosis (Zarubin and Han, 2005; Guo et al., 2020).”
BackgroundHost Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2
Inohara, N., Ogura, Y., Fontalba, A., Gutierrez, O., Pons, F., Crespo, J., Fukase, K., Inamura, S., Kusumoto, S., Hashimoto, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200673200 · Cited by 1,696 · cited 1×
“, 2006), whereas NOD2 is activated by muramyl dipeptide (MDP) (Girardin et al., 2003b; Inohara et al., 2003; Hasegawa et al., 2006).”
BackgroundNod1 Detects a Unique Muropeptide from Gram-Negative Bacterial Peptidoglycan
Girardin, S. E., Boneca, I. G., Carneiro, L. A. M., Antignac, A., Jéhanno, M., Viala, J., Tedin, K., Taha, M.-K., Labigne, A., Zäthringer, U., et al. (2003) · Science · doi:10.1126/science.1084677 · Cited by 1,577
ERK/MAPK signalling pathway and tumorigenesis (Review)
Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475 · cited 1×
“The MAPK signaling pathways regulate several cellular processes, including proliferation, differentiation, inflammation, and apoptosis (Zarubin and Han, 2005; Guo et al., 2020).”
BackgroundNod2, a Nod1/Apaf-1 Family Member That Is Restricted to Monocytes and Activates NF-κB
Ogura, Y., Inohara, N., Benito, A., Chen, F. F., Yamaoka, S., & Núñez, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008072200 · Cited by 1,361
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356 · cited 1×
“designed the RIPK2 PROTAC12 by conjugating, via a PEG linker, a VonHippelLindau (VHL) E3 ligase ligand to the 7-position of the quinoline ring (Figure 15) (Bondeson et al., 2015).”
Chamaillard, M., Hashimoto, M., Horie, Y., Masumoto, J., Qiu, S., Saab, L., Ogura, Y., Kawasaki, A., Fukase, K., Kusumoto, S., et al. (2003) · Nature Immunology · doi:10.1038/ni945 · Cited by 1,323 · cited 1×
“bacteria (Girardin et al., 2003a; Chamaillard et al., 2003; Hasegawa et al., 2006), whereas NOD2 is activated by muramyl dipeptide (MDP) (Girardin et al.”
BackgroundKinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245 · cited 1×
“In contrast to type I kinase inhibitors, type II kinase inhibitors target the inactive conformation of kinases by interacting with the catalytic site of unphosphorylated proteins (Bhullar et al., 2018).”
BackgroundKinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024 · cited 15×
“They acted as competitive inhibitors for ATP by binding to the ATP-binding pocket of their target kinase.”
BackgroundInfluentialKinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009 · cited 15×
“They acted as competitive inhibitors for ATP by binding to the ATP-binding pocket of their target kinase.”
BackgroundInfluentialLesage, S., Zouali, H., Cézard, J.-P., Colombel, J.-F., Belaiche, J., Almer, S., Tysk, C., O'Morain, C., Gassull, M., Binder, V., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/339432 · Cited by 997 · cited 1×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundRICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems
Kobayashi, K., Inohara, N., Hernandez, L. D., Galán, J. E., Núñez, G., Janeway, C. A., Medzhitov, R., & Flavell, R. A. (2002) · Nature · doi:10.1038/416194a · Cited by 893 · cited 5×
“RIPK2 signaling in innate immunity RIPK2 is expressed in antigen-presenting dendritic cells and macrophages, and plays a pivotal role in innate immunity as it participates in signaling through NODs (NOD1 and NOD2), and possibly TLRs (Kobayashi et al., 2002).”
BackgroundInfluentialNOD1 and NOD2: Signaling, Host Defense, and Inflammatory Disease
Caruso, R., Warner, N., Inohara, N., & Núñez, G. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.010 · Cited by 830 · cited 2×
“While TLRs sense microbes at the cell surface or in endosomes, NODs recognize bacterial peptidoglycan (PGN) components in the cytoplasm (Caruso et al., 2014).”
BackgroundNOD-Like Receptors: Role in Innate Immunity and Inflammatory Disease
Chen, G., Shaw, M. H., Kim, Y.-G., & Nuñez, G. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092239 · Cited by 772 · cited 2×
“found in recently published reviews (Chen et al., 2009; Jun et al., 2013; Caruso et al., 2014; Irving et al., 2014; Humphries et al., 2015; Ermine et al., 2022).”
An Induced Proximity Model for NF-κB Activation in the Nod1/RICK and RIP Signaling Pathways
Inohara, N., Koseki, T., Lin, J., del Peso, L., Lucas, P. C., Chen, F. F., Ogura, Y., & Núñez, G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003415200 · Cited by 540 · cited 1×
“The intermediate region and/or KD of RIPK2 is involved in the binding with IKKγ, whereas the CARD domain is dispensable (Inohara et al., 2000).”
BackgroundRICK/RIP2 Mediates Innate Immune Responses Induced through Nod1 and Nod2 but Not TLRs
Park, J.-H., Kim, Y.-G., McDonald, C., Kanneganti, T.-D., Hasegawa, M., Body-Malapel, M., Inohara, N., & Núñez, G. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2380 · Cited by 530 · cited 1×
“Moreover, the role of RIPK2 in TLR signaling remains less defined and requires further studies to resolve ongoing controversy (Kobayashi et al., 2002; Park et al., 2007; Hall et al., 2008).”
BackgroundA critical role of RICK/RIP2 polyubiquitination in Nod‐induced NF‐κB activation
Hasegawa, M., Fujimoto, Y., Lucas, P. C., Nakano, H., Fukase, K., Núñez, G., & Inohara, N. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601962 · Cited by 522 · cited 12×
“IKK-mediated phosphorylation of the NF-κB inhibitor IκBα leads to its pUb and subsequent degradation through the ubiquitin-proteasome system (UPS).”
BackgroundInfluentialRIP2 Is a Novel NF-κB-activating and Cell Death-inducing Kinase
McCarthy, J. V., Ni, J., & Dixit, V. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.27.16968 · Cited by 436
Involvement of receptor-interacting protein 2 in innate and adaptive immune responses
Chin, A. I., Dempsey, P. W., Bruhn, K., Miller, J. F., Xu, Y., & Cheng, G. (2002) · Nature · doi:10.1038/416190a · Cited by 401 · cited 2×
“RIPK2 also plays a role in adaptive immunity as it is involved in CD4 T cell proliferation and T-helper cell development (Chin et al., 2002).”
BackgroundCrystal Structure of NLRC4 Reveals Its Autoinhibition Mechanism
Hu, Z., Yan, C., Liu, P., Huang, Z., Ma, R., Zhang, C., Wang, R., Zhang, Y., Martinon, F., Miao, D., et al. (2013) · Science · doi:10.1126/science.1236381 · Cited by 399 · cited 1×
“In the resting state, NOD1 and NOD2 reside in an autoinhibited monomeric configuration in the cytosol with the LRRs folds over the NOD region (Hu et al., 2013).”
BackgroundAbbott, D. W., Wilkins, A., Asara, J. M., & Cantley, L. C. (2004) · Current Biology · doi:10.1016/j.cub.2004.12.032 · Cited by 374 · cited 2×
“IKKγ, a key component of the IKK signaling complex, is then ubiquitinated at Lys285 (Abbott et al., 2004).”
BackgroundRegulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition
Tanabe, T., Chamaillard, M., Ogura, Y., Zhu, L., Qiu, S., Masumoto, J., Ghosh, P., Moran, A., Predergast, M. M., Tromp, G., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600175 · Cited by 362 · cited 1×
“The HD2 helix domain in the NOD module mediates conformational changes of the NBD, WH, and HD1 to allow ADP-ATP exchange (Tanabe et al., 2004).”
BackgroundBertrand, M. J. M., Doiron, K., Labbé, K., Korneluk, R. G., Barker, P. A., & Saleh, M. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.011 · Cited by 340
Immune-mediated inflammatory disease therapeutics: past, present and future
McInnes, I. B., & Gravallese, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00603-1 · Cited by 337 · cited 2×
“Modern immunotherapies focus on precisely regulating immune responses (Kany et al., 2019; McInnes and Gravallese, 2021).”
BackgroundMcGovern, D. P. B., Hysi, P., Ahmad, T., van Heel, D. A., Moffatt, M. F., Carey, A., Cookson, W. O. C., & Jewell, D. P. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi135 · Cited by 319 · cited 1×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundIdentification of CARDIAK, a RIP-like kinase that associates with caspase-1
Thome, M., Hofmann, K., Burns, K., Martinon, F., Bodmer, J.-L., Mattmann, C., & Tschopp, J. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00352-1 · Cited by 318 · cited 1×
“RIPK2 is broadly expressed in tissues including pancreas and placenta (Thome et al., 1998).”
BackgroundEndosomes are specialized platforms for bacterial sensing and NOD2 signalling
Nakamura, N., Lill, J. R., Phung, Q., Jiang, Z., Bakalarski, C., de Mazière, A., Klumperman, J., Schlatter, M., Delamarre, L., & Mellman, I. (2014) · Nature · doi:10.1038/nature13133 · Cited by 313 · cited 1×
“After peptidoglycans (PGN) is uptaken into cells, NOD1 and NOD2 are activated by direct ligand-receptor interactions (Lee et al., 2009; Grimes et al., 2012; Mo et al., 2012; Nakamura et al., 2014).”
BackgroundNOD1 variation, immunoglobulin E and asthma
Hysi, P., Kabesch, M., Moffatt, M. F., Schedel, M., Carr, D., Zhang, Y., Boardman, B., von Mutius, E., Weiland, S. K., Leupold, W., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi087 · Cited by 267 · cited 1×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundSmall Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265 · cited 14×
“They acted as competitive inhibitors for ATP by binding to the ATP-binding pocket of their target kinase.”
BackgroundInfluentialIrving, A. T., Mimuro, H., Kufer, T. A., Lo, C., Wheeler, R., Turner, L. J., Thomas, B. J., Malosse, C., Gantier, M. P., Casillas, L. N., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.04.001 · Cited by 249
Inohara, N., del Peso, L., Koseki, T., Chen, S., & Núñez, G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.12296 · Cited by 245
RIP kinases: key decision makers in cell death and innate immunity
Humphries, F., Yang, S., Wang, B., & Moynagh, P. N. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.126 · Cited by 241 · cited 1×
“found in recently published reviews (Chen et al., 2009; Jun et al., 2013; Caruso et al., 2014; Irving et al., 2014; Humphries et al., 2015; Ermine et al., 2022).”
Brehmer, D., Greff, Z., Godl, K., Blencke, S., Kurtenbach, A., Weber, M., Müller, S., Klebl, B., Cotten, M., Kéri, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.379.65.2 · Cited by 241 · cited 1×
“Gefitinib and adezmapimod were also reported by others to inhibit RIPK2 activity (Argast et al., 2005; Brehmer et al., 2005; Hollenbach et al., 2005; Windheim et al., 2007).”
BackgroundExtended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
Mares, A., Miah, A. H., Smith, I. E. D., Rackham, M., Thawani, A. R., Cryan, J., Haile, P. A., Votta, B. J., Beal, A. M., Capriotti, C., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0868-6 · Cited by 232
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Hu, Z., & Crews, C. M. (2022) · ChemBioChem · doi:10.1002/cbic.202100270 · Cited by 231 · cited 1×
“This catalytic nature of PROTACs distinguishes them from traditional inhibitors (Békés et al., 2022; Hu and Crews, 2022).”
BackgroundYang, Y., Yin, C., Pandey, A., Abbott, D., Sassetti, C., & Kelliher, M. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703079200 · Cited by 227 · cited 10×
“IKK-mediated phosphorylation of the NF-κB inhibitor IκBα leads to its pUb and subsequent degradation through the ubiquitin-proteasome system (UPS).”
BackgroundInfluentialLee, J., Tattoli, I., Wojtal, K. A., Vavricka, S. R., Philpott, D. J., & Girardin, S. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033670 · Cited by 214 · cited 1×
“After peptidoglycans (PGN) is uptaken into cells, NOD1 and NOD2 are activated by direct ligand-receptor interactions (Lee et al., 2009; Grimes et al., 2012; Mo et al., 2012; Nakamura et al., 2014).”
BackgroundMolecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide
Windheim, M., Lang, C., Peggie, M., Plater, L. A., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20061704 · Cited by 200 · cited 11×
“IKK-mediated phosphorylation of the NF-κB inhibitor IκBα leads to its pUb and subsequent degradation through the ubiquitin-proteasome system (UPS).”
BackgroundInfluentialThe Innate Immune Protein Nod2 Binds Directly to MDP, a Bacterial Cell Wall Fragment
Grimes, C. L., Ariyananda, L. D. Z., Melnyk, J. E., & O’Shea, E. K. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303883c · Cited by 195 · cited 1×
“After peptidoglycans (PGN) is uptaken into cells, NOD1 and NOD2 are activated by direct ligand-receptor interactions (Lee et al., 2009; Grimes et al., 2012; Mo et al., 2012; Nakamura et al., 2014).”
Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses
Tigno-Aranjuez, J. T., Asara, J. M., & Abbott, D. W. (2010) · Genes & Development · doi:10.1101/gad.1964410 · Cited by 192
Inflammasome, Inflammation, and Tissue Homeostasis
Rathinam, V. A. K., & Chan, F. K.-M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.01.004 · Cited by 190 · cited 1×
“, 2008), therapeutic targeting the NOD2/RIPK2 pathway holds potentials to reestablish gut tissue homeostasis (Parlato and Yeretssian, 2014; Rathinam and Chan, 2018).”
BackgroundCoordinated Regulation of Toll-Like Receptor and NOD2 Signaling by K63-Linked Polyubiquitin Chains
Abbott, D. W., Yang, Y., Hutti, J. E., Madhavarapu, S., Kelliher, M. A., & Cantley, L. C. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00270-07 · Cited by 183 · cited 10×
“IKK-mediated phosphorylation of the NF-κB inhibitor IκBα leads to its pUb and subsequent degradation through the ubiquitin-proteasome system (UPS).”
BackgroundInfluentialHasegawa, M., Yang, K., Hashimoto, M., Park, J.-H., Kim, Y.-G., Fujimoto, Y., Nuñez, G., Fukase, K., & Inohara, N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602638200 · Cited by 176 · cited 2×
“, 2006), whereas NOD2 is activated by muramyl dipeptide (MDP) (Girardin et al., 2003b; Inohara et al., 2003; Hasegawa et al., 2006).”
BackgroundMo, J., Boyle, J. P., Howard, C. B., Monie, T. P., Davis, B. K., & Duncan, J. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.344283 · Cited by 168 · cited 1×
“After peptidoglycans (PGN) is uptaken into cells, NOD1 and NOD2 are activated by direct ligand-receptor interactions (Lee et al., 2009; Grimes et al., 2012; Mo et al., 2012; Nakamura et al., 2014).”
Takeuchi, M., Mizuki, N., Meguro, A., Ombrello, M. J., Kirino, Y., Satorius, C., Le, J., Blake, M., Erer, B., Kawagoe, T., et al. (2017) · Nature Genetics · doi:10.1038/ng.3786 · Cited by 166 · cited 1×
“Ile259Thr) was recently identified as a susceptibility locus for Behcet’s disease in Turkish population (Takeuchi et al., 2017).”
BackgroundA RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production
Nachbur, U., Stafford, C. A., Bankovacki, A., Zhan, Y., Lindqvist, L. M., Fiil, B. K., Khakham, Y., Ko, H.-J., Sandow, J. J., Falk, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7442 · Cited by 148
Hollenbach, E., Vieth, M., Roessner, A., Neumann, M., Malfertheiner, P., & Naumann, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500966200 · Cited by 148 · cited 2×
“In colitis models, adezmapimod improved disease scores, reduced intestinal inflammation, and suppressed mRNA levels of pro-inflammatory cytokines (Hollenbach et al., 2005).”
BackgroundShaw, P. J., Barr, M. J., Lukens, J. R., McGargill, M. A., Chi, H., Mak, T. W., & Kanneganti, T.-D. (2011) · Immunity · doi:10.1016/j.immuni.2010.12.015 · Cited by 143
ITCH K63-Ubiquitinates the NOD2 Binding Protein, RIP2, to Influence Inflammatory Signaling Pathways
Tao, M., Scacheri, P. C., Marinis, J. M., Harhaj, E. W., Matesic, L. E., & Abbott, D. W. (2009) · Current Biology · doi:10.1016/j.cub.2009.06.038 · Cited by 141 · cited 1×
“As a result, RIPK2 is activated by auto-phosphorylation and subsequently polyubiquitinated by E3 ligases for nondegradative polyubiquitination (pUb) on Lys209 via Lys63-linked pUb (Hasegawa et al., 2008; Bertrand et al., 2009; Tao et al., 2009; Marinis et al., 2011; Yang et al., 2013; Zhang et al., 2014).”
BackgroundInflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors
Canning, P., Ruan, Q., Schwerd, T., Hrdinka, M., Maki, J. L., Saleh, D., Suebsuwong, C., Ray, S. S., Brennan, P. E., Cuny, G. D., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.017 · Cited by 138 · cited 3×
“Regorafenib and sorafenib were suggested to bind to RIPK2 similarly despite lower potency in vitro (Canning et al., 2015).”
BackgroundHaile, P. A., Votta, B. J., Marquis, R. W., Bury, M. J., Mehlmann, J. F., Singhaus, R., Charnley, A. K., Lakdawala, A. S., Convery, M. A., Lipshutz, D. B., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00211 · Cited by 119
Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis
Yang, S., Wang, B., Humphries, F., Jackson, R. P., Healy, M. E., Bergin, R., Aviello, G., Hall, B. J., McNamara, D. A., Darby, T. M., et al. (2013) · Nature Immunology · doi:10.1038/ni.2669 · Cited by 110
In Vivo Inhibition of RIPK2 Kinase Alleviates Inflammatory Disease
Tigno-Aranjuez, J. T., Benderitter, P., Rombouts, F., Deroose, F., Bai, X., Mattioli, B., Cominelli, F., Pizarro, T. T., Hoflack, J., & Abbott, D. W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.591388 · Cited by 110 · cited 9×
“The efficacy of BI 706039 was further probed in the TRUCmouse model of IBD.”
BackgroundInfluentialCellular and molecular mechanisms underlying NOD 2 risk‐associated polymorphisms in Crohn's disease
Strober, W., Asano, N., Fuss, I., Kitani, A., & Watanabe, T. (2014) · Immunological Reviews · doi:10.1111/imr.12193 · Cited by 104 · cited 2×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundSarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium acnes
Tanabe, T., Ishige, I., Suzuki, Y., Aita, Y., Furukawa, A., Ishige, Y., Uchida, K., Suzuki, T., Takemura, T., Ikushima, S., et al. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.07.006 · Cited by 104 · cited 1×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundRIP2 Is a Raf1-activated Mitogen-activated Protein Kinase Kinase
Navas, T. A., Baldwin, D. T., & Stewart, T. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.47.33684 · Cited by 96
Rosé, C. D., Martin, T. M., & Wouters, C. H. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328349c430 · Cited by 95 · cited 1×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundStructural basis of death domain signaling in the p75 neurotrophin receptor
Lin, Z., Tann, J. Y., Goh, E. T., Kelly, C., Lim, K. B., Gao, J. F., & Ibanez, C. F. (2015) · eLife · doi:10.7554/elife.11692 · Cited by 91 · cited 2×
“The structure of RIPK2 CARD shares similar features with NOD1 CARD, including the arrangement of all but the last of the a-helices (Fridh and Rittinger, 2012; Lin et al., 2015; Maharana et al., 2015; Goncharuk et al., 2018; Maharana et al., 2021).”
BackgroundMethodHo, G., Cartwright, J. A., Thompson, E. J., Bain, C. C., & Rossi, A. G. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa045 · Cited by 90 · cited 8×
“The efficacy of BI 706039 was further probed in the TRUCmouse model of IBD.”
BackgroundInfluentialLee, P. Y., Yeoh, Y., & Low, T. Y. (2022) · FEBS Journal · doi:10.1111/febs.16442 · Cited by 84 · cited 15×
“They acted as competitive inhibitors for ATP by binding to the ATP-binding pocket of their target kinase.”
BackgroundInfluentialRIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases
Honjo, H., Watanabe, T., Kamata, K., Minaga, K., & Kudo, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.650403 · Cited by 83 · cited 1×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundNOD-like receptors in intestinal homeostasis and epithelial tissue repair
Parlato, M., & Yeretssian, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069594 · Cited by 79 · cited 1×
“, 2008), therapeutic targeting the NOD2/RIPK2 pathway holds potentials to reestablish gut tissue homeostasis (Parlato and Yeretssian, 2014; Rathinam and Chan, 2018).”
BackgroundOptimization of a Series of RIPK2 PROTACs
Miah, A. H., Smith, I. E., Rackham, M. D., Mares, A., Thawani, A. R., Nagilla, R., Haile, P. A., Votta, B. J., Gordon, L. J., Watt, G. F., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01118 · Cited by 76 · cited 1×
“optimized the structure of RIPK2 PROTAC 13 by first replacing the RIPK2 binding moiety with the aminopyrazolylquinazoline binder (Miah et al., 2021).”
MethodInhibition of RIP2/RICK/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK
Argast, G. M., Fausto, N., & Campbell, J. S. (2005) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-3701-0 · Cited by 75 · cited 2×
“Gefitinib and adezmapimod were also reported by others to inhibit RIPK2 activity (Argast et al., 2005; Brehmer et al., 2005; Hollenbach et al., 2005; Windheim et al., 2007).”
BackgroundRICK/RIP2 is a NOD2-independent nodal point of gut inflammation
Watanabe, T., Minaga, K., Kamata, K., Sakurai, T., Komeda, Y., Nagai, T., Kitani, A., Tajima, M., Fuss, I. J., Kudo, M., et al. (2019) · International Immunology · doi:10.1093/intimm/dxz045 · Cited by 72
Marinis, J. M., Homer, C. R., McDonald, C., & Abbott, D. W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.189308 · Cited by 65 · cited 1×
“As a result, RIPK2 is activated by auto-phosphorylation and subsequently polyubiquitinated by E3 ligases for nondegradative polyubiquitination (pUb) on Lys209 via Lys63-linked pUb (Hasegawa et al., 2008; Bertrand et al., 2009; Tao et al., 2009; Marinis et al., 2011; Yang et al., 2013; Zhang et al., 2014).”
BackgroundChen, J., Haller, C. A., Jernigan, F. E., Koerner, S. K., Wong, D. J., Wang, Y., Cheong, J. E., Kosaraju, R. S., Kwan, J., Park, D., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay8230 · Cited by 65
Self-citationVieira, S. M., Cunha, T. M., França, R. F. D. O., Pinto, L. G., Talbot, J., Turato, W. M., Lemos, H. D. P., Lima, J. B., Verri, W. A., Jr., Almeida, S. C. L., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1004190 · Cited by 64
Haile, P. A., Casillas, L. N., Votta, B. J., Wang, G. Z., Charnley, A. K., Dong, X., Bury, M. J., Romano, J. J., Mehlmann, J. F., King, B. W., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00575 · Cited by 63 · cited 1×
“, quinoline to quinazoline; indazole to benzothiazole) resulted in the 4-aminoquinazoline series (4, Figure 6; Figure 7D) that had a divergent structure-activity relationship (SAR) in inhibitory activities for RIPK2 and hERG ion channel (Haile et al., 2019).”
BackgroundRIP2 activity in inflammatory disease and implications for novel therapeutics
Jun, J., Cominelli, F., & Abbott, D. W. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0213109 · Cited by 61 · cited 1×
“found in recently published reviews (Chen et al., 2009; Jun et al., 2013; Caruso et al., 2014; Irving et al., 2014; Humphries et al., 2015; Ermine et al., 2022).”
Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases
He, X., Ros, S. D., Nelson, J. T., Zhu, X., Jiang, T., Barun, O., Jiang, S., Michellys, P., Iskandar, M., Espinola, S., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00258 · Cited by 57 · cited 1×
“from Novartis reported their lead identification and optimization program for the discovery of RIPK2 inhibitors (He et al., 2017).”
BackgroundThe balance of power: innate lymphoid cells in tissue inflammation and repair
Castellanos, J. G., & Longman, R. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124617 · Cited by 57 · cited 8×
“The efficacy of BI 706039 was further probed in the TRUCmouse model of IBD.”
BackgroundInfluentialActivation of NOD2-mediated intestinal pathway in a pediatric population with Crohnʼs disease
Negroni, A., Stronati, L., Pierdomenico, M., Tirindelli, D., Nardo, G. D., Mancini, V., Maiella, G., & Cucchiara, S. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20907 · Cited by 53 · cited 1×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundGenetics of Behçet's Disease: Functional Genetic Analysis and Estimating Disease Heritability
Ortiz‐Fernández, L., & Sawalha, A. H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.625710 · Cited by 51 · cited 1×
“Behcet’s disease is a systemic inflammatory disease that lead to recurring ulcers in the mouth and other tissues (Ortiz-Fernández and Sawalha, 2021).”
BackgroundHall, H. T. L., Wilhelm, M., Saibil, S. D., Mak, T. W., Flavell, R. A., & Ohashi, P. S. (2007) · European Journal of Immunology · doi:10.1002/eji.200737393 · Cited by 49 · cited 2×
“However, the role of RIPK2 in adaptive immunity is still controversial (Hall et al., 2008).”
BackgroundThe Tandem CARDs of NOD2: Intramolecular Interactions and Recognition of RIP2
Fridh, V., & Rittinger, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034375 · Cited by 47 · cited 4×
“The helix α1 consists of two smaller helices (α1a, α1b), which are connected by a sharp kink (Fridh and Rittinger, 2012).”
BackgroundMethodInfluentialThe Role of RIP2 in p38 MAPK Activation in the Stressed Heart
Jacquet, S., Nishino, Y., Kumphune, S., Sicard, P., Clark, J. E., Kobayashi, K. S., Flavell, R. A., Eickhoff, J., Cotten, M. L., & Marber, M. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707750200 · Cited by 46
Structures of the inactive and active states of RIP2 kinase inform on the mechanism of activation
Pellegrini, E., Signor, L., Singh, S., Boeri Erba, E., & Cusack, S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177161 · Cited by 44 · cited 1×
“Crystallographic studies of ligand bound and apo (ligand-free) RIPK2 KD have provided insightful three dimensional (3D) structural information (Canning et al., 2015; Charnley et al., 2015; Pellegrini et al., 2017).”
BackgroundCharnley, A. K., Convery, M. A., Shah, A. L., Jones, E. J., Hardwicke, P., Bridges, A. M., Ouellette, M. T., Totoritis, R. D., Schwartz, B. K., King, B. W., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.09.038 · Cited by 40 · cited 3×
“from GlaxoSmithKline (GSK) described a novel RIPK2 inhibitor chemotype–the benzimidazole analogue 1 (IC50 = 500 nM) through GSK encoded library technology (ELT) collection (Figure 4) (Charnley et al., 2015).”
BackgroundMethodTalreja, J., Talwar, H. S., Ahmad, N., Rastogi, R., & Samavati, L. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600258 · Cited by 40 · cited 1×
“found the evidence for the contribution of RIPK2 to the pathology of sarcoidosis, a multisystem granulomatous disease that primarily occurs in the lungs (Talreja et al., 2016).”
BackgroundMucosal NOD2 expression and NF-κB activation in pediatric Crohnʼs disease
Stronati, L., Negroni, A., Merola, P., Pannone, V., Borrelli, O., Cirulli, M., Annese, V., & Cucchiara, S. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20332 · Cited by 37 · cited 2×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundYuan, X., Chen, Y. X., Tang, M., Wei, Y., Shi, M., Yang, Y., Zhou, Y., Yang, T., Liu, J., Liu, K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00604 · Cited by 36
Haile, P. A., Casillas, L., Bury, M. J., Mehlmann, J. F., Singhaus, R. R., Charnley, A. K., Hughes, T. V., DeMartino, M. P., Wang, G. Z., Romano, J. J., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00344 · Cited by 34 · cited 13×
“Replacing the benzo-fused indazole ring in GSK583 with two methyl groups at the 3- and 4-positions of the pyrazole ring kept the essential hydrophobic interactions of GSK583 with the back pocket of RIPK2, as demonstrated by the co-crystal structure of RIPK2 in complex with 3 (Figure 7C).”
BackgroundInfluentialRole of Receptor Interacting Protein (RIP) kinases in cancer
Ermine, K., Yu, J., & Zhang, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.10.007 · Cited by 34 · cited 1×
“found in recently published reviews (Chen et al., 2009; Jun et al., 2013; Caruso et al., 2014; Irving et al., 2014; Humphries et al., 2015; Ermine et al., 2022).”
Hong, L., Quinn, C. M., & Jia, Y. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.04.033 · Cited by 32 · cited 1×
“A RIPK2 homogenous time-resolved fluorescence (HTRF) ADP transcreener assay, which measures kinase activity by following the formation of ADP using an anti-ADP antibody labeled with europium (Eu) and a d2-labeled ADP (tracer) (Hong et al., 2009), was applied to confirm the activity of virtual hits.”
MethodMaharana, J., Dehury, B., Sahoo, B. R., Jena, I., Bej, A., Panda, D., Sahoo, B. R., Patra, M. C., & Pradhan, S. K. (2015) · Molecular BioSystems · doi:10.1039/c5mb00212e · Cited by 31
Stronati, L., Negroni, A., Pierdomenico, M., D’Ottavio, C., Tirindelli, D., Nardo, G. D., Oliva, S., Viola, F., & Cucchiara, S. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.04.003 · Cited by 31 · cited 1×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundA hyperactivating proinflammatory RIPK2 allele associated with early-onset osteoarthritis
Jurynec, M. J., Sawitzke, A. D., Beals, T. C., Redd, M. J., Stevens, J., Otterud, B., Leppert, M., & Grunwald, D. J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy132 · Cited by 28 · cited 2×
“showed that RIPK2 significantly upregulated genes encoding NF-κB components, proinflammatory cytokines and genes downstream of proinflammatory cytokine signaling similar to RIPK2 (Jurynec et al., 2018).”
BackgroundHaffner, C. D., Charnley, A. K., Aquino, C. J., Casillas, L., Convery, M. A., Cox, J. A., Elban, M. A., Goodwin, N. C., Gough, P. J., Haile, P. A., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00141 · Cited by 26
The E3 Ligase RNF34 is a Novel Negative Regulator of the NOD1 Pathway
Zhang, R., Zhao, J., Song, Y., Wang, X., Wang, L., Xu, J., Song, C. H., & Liu, F. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000362972 · Cited by 25 · cited 1×
“As a result, RIPK2 is activated by auto-phosphorylation and subsequently polyubiquitinated by E3 ligases for nondegradative polyubiquitination (pUb) on Lys209 via Lys63-linked pUb (Hasegawa et al., 2008; Bertrand et al., 2009; Tao et al., 2009; Marinis et al., 2011; Yang et al., 2013; Zhang et al., 2014).”
BackgroundErmann, J., Matmusaev, M., Haley, E. K., Braun, C., Jost, F., Mayer‐Wrangowski, S. C., Hsiao, P., Ting, N., Li, L., Terenzio, D., et al. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00163.2021 · Cited by 25
BindingDB (2021) · PubMed · doi:10.7270/q2ws8xkf · Cited by 20
Modeling conformational flexibility of kinases in inactive states
Schwarz, D., Merget, B., Deane, C. M., & Fulle, S. (2019) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25756 · Cited by 19 · cited 1×
“The co-crystal structure of RIPK2 with ponatinib showed that it occupied the ATP pocket of inactive RIPK2 with the “DFG-Asp out, αC-Glu in” configuration, characteristic of kinases in an inactive conformation (Figure 14) (Schwarz et al., 2019).”
BackgroundNovel Thienopyridines as RIPK2 Inhibitors for Treating Inflammatory Bowel Disease
Sabnis, R. W. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00591 · Cited by 15
Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML
Wu, H. Y., Wang, A., Zhou, Q., Li, X., Chen, C., Yu, K., Zou, F., Hu, C., Wang, W., Zhao, Z., et al. (2016) · Leukemia · doi:10.1038/leu.2016.151 · Cited by 14
Goncharuk, S. A., Artemieva, L. E., Tabakmakher, V. М., Arseniev, A. S., & Mineev, K. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206244 · Cited by 14
Maharana, J., Maharana, D., Bej, A., Sahoo, B. R., Panda, D., Wadavrao, S. B., Vats, A., Pradhan, S. K., & De, S. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c06176 · Cited by 8 · cited 2×
“The structure of RIPK2 CARD shares similar features with NOD1 CARD, including the arrangement of all but the last of the a-helices (Fridh and Rittinger, 2012; Lin et al., 2015; Maharana et al., 2015; Goncharuk et al., 2018; Maharana et al., 2021).”
BackgroundMethod
Cited by
Phelps, C. M., Willis, N. B., Duan, T., Lee, A. H., Zhang, Y., Rodriguez J, D. M., Pandey, S. P., Laughlin, C. R., Rosen, A. B. I., McPherson, A. C., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.018 · Cited by 91
Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives
Yang, X., Guo, H., & Zou, M. (2026) · Molecular Biomedicine · doi:10.1186/s43556-025-00395-z · Cited by 92
“Aberrant activation of RIPK2 is closely associated with increased expression of signaling molecules in the colonic mucosa of IBD patients, and blocking RIPK2 activation effectively inhibits the development of experimental colitis in mice [463, 464].”
Endotoxin tolerance and trained immunity: breaking down immunological memory barriers
López‐Collazo, E., & del Fresno, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1393283 · Cited by 60
Host–pathobiont interactions in Crohn’s disease
Caruso, R., Lo, B. C., Chen, G., & Núñez, G. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00997-y · Cited by 44
“A critical role of NOD2 as an intestinal microbial sensor in Crohn’s disease is further strengthened by the observation that genetic variants in RIPK2 that encode an essential kinase required for NOD2 signalling, are also linked to Crohn’s disease 69 .”
Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease
Lai, Y., Wang, X., Sun, X. F., Wu, S., Chen, X., Yang, C., Zhang, W., Yu, X., Tong, Y., Ma, F., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115647 · Cited by 24
Metadata
- Authors
- Pham, A.-T., Ghilardi, A. F., & Sun, L.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Sun, Lijun
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-03-07
- Volume
- 14
- Pages
- 1127722-1127722
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10028200
- OpenAlex
- W4323364425
- Cited by
- 40
- References
- 103
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 11 · 2023: 7
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- RIPK2, NOD2 signaling, Toll-like receptor signaling, NF-κB activation, MAPK signaling, inflammatory cytokines, inflammatory diseases, asthma, sarcoidosis, inflammatory bowel disease, multiple sclerosis, Blau syndrome, innate immunity, immunomodulation, small molecule drug candidates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.